SCHEMBL30009048

SCHEMBL30009048

COC(=O)/C(=C/c1ccc(Cl)cc1OC)N=[N+]=[N-]

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 3/20 0.38
▸ LMNA P02545 2/20 0.38
▸ KDM4E B2RXH2 2/20 0.38
▸ HPGD P15428 2/20 0.38
▸ MEN1 O00255 2/20 0.37
▸ KMT2A Q03164 2/20 0.37
▸ NPC1 O15118 1/20 0.37
▸ L3MBTL1 Q9Y468 1/20 0.37
▸ CTDSP1 Q9GZU7 1/20 0.36
▸ FLT1 P17948 1/20 0.36
▸ FLT4 P35916 1/20 0.36
▸ KDR P35968 1/20 0.36
▸ ALDH1A1 P00352 4/20 0.35
▸ GAA P10253 1/20 0.35
▸ PTGES2 Q9H7Z7 1/20 0.35
▸ GLA P06280 1/20 0.35
▸ TRPV4 Q9HBA0 1/20 0.35
▸ KCNMA1 Q12791 1/20 0.34
▸ GRIK1 P39086 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24113456 1.00 MAPT (0.38) MAPTLMNAKDM4EHPGDMEN1
SCHEMBL29015369 0.90 KDM4E (0.48) MAPTLMNAKDM4EMEN1KMT2A
SCHEMBL24189153 0.90 KDM4E (0.48) MAPTLMNAKDM4EMEN1KMT2A
SCHEMBL23709904 0.88 RHEB (0.35) MAPTLMNAMEN1KMT2AALDH1A1
SCHEMBL29015648 0.87 KMT2A (0.34) MAPTLMNAKDM4EMEN1KMT2A
SCHEMBL24190445 0.86 RORC (0.36) MEN1KMT2AGRIK1
SCHEMBL20536125 0.86 L3MBTL1 (0.39) MAPTLMNAMEN1KMT2AL3MBTL1
SCHEMBL20536123 0.86 L3MBTL1 (0.39) MAPTLMNAMEN1KMT2AL3MBTL1
SCHEMBL29015469 0.86 RORC (0.36) MEN1KMT2AGRIK1
SCHEMBL27891901 0.86 MAPT (0.48) MAPTKDM4EHPGDMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260116857-A1 INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOFS PARDES BIOSCIENCES INC (US) 2026-04-30 — — US disclosed
US-12145911-B2 Inhibitors of cysteine proteases and methods of use thereof Pardes Biosciences, Inc. (US) 2024-11-19 — — US disclosed
US-20240270693-A1 INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF Pardes Biosciences, Inc. (US) 2024-08-15 — — US disclosed
US-20230212152-A1 INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF Pardes Biosciences, Inc. 2023-07-06 — — US disclosed
EP-4161902-A1 INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF Pardes Biosciences, Inc. (US) 2023-04-12 — — EP disclosed
US-11524940-B1 Inhibitors of cysteine proteases and methods of use thereof Pardes Biosciences, Inc. (US) 2022-12-13 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260116857-A1 INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOFS CTRC, CTRL, CTSL MAPT 4572/4885LMNA 1889/4885KDM4E 2746/4885
US-20240270693-A1 INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF CTRL, CTSV, CTSL MAPT 1905/4885LMNA 2486/4885KDM4E 2930/4885
US-12145911-B2 Inhibitors of cysteine proteases and methods of use thereof CTRL, CTSV, CTSL MAPT 1905/4885LMNA 2486/4885KDM4E 2930/4885
US-11524940-B1 Inhibitors of cysteine proteases and methods of use thereof CTRL, CTSV, CTSL MAPT 1905/4885LMNA 2486/4885KDM4E 2930/4885
US-20230212152-A1 INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF CTRL, CTSL, CTSV MAPT 2314/4885LMNA 2202/4885KDM4E 3122/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback